title: Magnetic Fe₃ O ₄ nanoparticles grafted with single-chain antibody (scFv) and docetaxel loaded β-cyclodextrin potential for ovarian cancer dual-targeting therapy.
abstract: In order to improve the therapeutic efficiency and reduce the side effects on nonpathological cells and tissues, targeting drug delivery systems have gained more and more attraction. Here, we report a novel dual-targeting drug delivery system for ovarian cancer therapy. The inner core was made of iron oxide (Fe3O4) nanoparticles, synthesized by co-precipitation method. It was further surface-functionalized with amine groups to link single-chain antibody (scFv) and β-cyclodextrin (β-CD). Docetaxel (TXT) was finally included in the grafted β-CD. FTIR and XPS confirmed the reactions. SEM found that the diameters of these Fe3O4 nanoparticles before and after functionalization were around 40 nm. Magnetization test showed that these particles were superparamagnetic. The in vitro release of TXT was concentration-driven and sustained, depending on the renewal rate of release medium. The in vitro flow chamber experiment revealed its magnetic targeting property; modified ELISA and static binding experiments displayed its good affinity to Endoglin, indicating that our drug delivery system has the potential to be dual-targeted to ovarian cancer tissue by externally applied magnetic field and native active binding of grafted scFv to Endoglin, overexpressed by ovarian cancer tissue. MTT assays showed that the TXT released from this drug delivery system continuously inhibited the growth of Skov3 ovarian cancer cells in 72h, better than the control raw TXT. All these results demonstrated a promising dual-targeting drug delivery system with great potential for ovarian cancer therapy.
authors: Key Laboratory for Biorheological Science and Technology of Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400044, China.
authors: Xiao
authors: X
authors: Huang
authors: Key Laboratory for Biorheological Science and Technology of Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400044, China.
authors: Caixia
authors: C
authors: Yi
authors: Key Laboratory for Biorheological Science and Technology of Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400044, China.
authors: Yijuan
authors: Y
authors: Fan
authors: Key Laboratory for Biorheological Science and Technology of Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400044, China.
authors: Yinxing
authors: Y
authors: Zhang
authors: Department of Obstetrics and Gynecology, Southwest Hospital, Third Military Medical University, Chongqing 400038, China.
authors: Limei
authors: L
authors: Zhao
authors: Department of Obstetrics and Gynecology, Southwest Hospital, Third Military Medical University, Chongqing 400038, China.
authors: Zhiqing
authors: Z
authors: Liang
authors: Key Laboratory for Biorheological Science and Technology of Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400044, China. Electronic address: panj@cqu.edu.cn.
authors: Jun
authors: J
authors: Pan
mesh_terms: D015703:Antigens, CD / Q000378:metabolism; D000970:Antineoplastic Agents / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D003692:Delayed-Action Preparations / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D000077143:Docetaxel; D004337:Drug Carriers / Q000737:chemistry*; D000071063:Endoglin; D005260:Female; D061307:Human Umbilical Vein Endothelial Cells; D006801:Humans; D058185:Magnetite Nanoparticles / Q000737:chemistry*; D010051:Ovarian Neoplasms / Q000378:metabolism*; D011956:Receptors, Cell Surface / Q000378:metabolism; D057127:Single-Chain Antibodies / Q000737:chemistry* / Q000378:metabolism; D043823:Taxoids / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology; D047392:beta-Cyclodextrins / Q000737:chemistry
chemical_list: D015703:Antigens, CD; D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D004337:Drug Carriers; C064206:ENG protein, human; D000071063:Endoglin; D058185:Magnetite Nanoparticles; D011956:Receptors, Cell Surface; D057127:Single-Chain Antibodies; D043823:Taxoids; D047392:beta-Cyclodextrins; D000077143:Docetaxel
keywords: Doctexal; Dual-targeting drug delivery system; Ovarian cancer; Sustained release